Table 1 Clinical characteristics and outcome data of COVID-19-infected patients
From: Predictors of COVID-19 outcome in type 2 diabetes mellitus: a hospital-based study
Variables | DM N = 45(%) | Not DM N = 59(%) | Test of significance | p value |
|---|---|---|---|---|
Male | 23 (51.1) | 24 (40.7) | χ2 = 1.12 | 0.29 |
Female | 22 (48.9) | 35 (59.3) | ||
Residence | ||||
Urban | 40 (91.5) | 45 (76.3) | χ2 = 2.72 | 0.09 |
Rural | 5 (8.5) | 14 (23.7) | ||
Smoking | 5 (11.1) | 4 (6.8) | FET = 0.61 | |
Yes | 40 (88.9) | 55 (93.2) | 0.44 | |
No | ||||
Diabetes complications | ||||
No | 22 (48.9) | |||
Nephropathy | 14 (31.1) | |||
Diabetic foot | 1 (2.2) | |||
Stroke | 2 (4.4) | |||
IHD | 6 (13.3) | |||
Medication of diabetic patients before COVID-19 infection | ||||
Diet control | 3 (6.7) | |||
Oral hypoglycemic | 30 (66.7) | |||
Insulin | 12 (26.7) | |||
Medication of DM after COVID infection | ||||
Diet control | 2 (4.4) | 44 (74.6) | FET = 50.9 | < .001** |
Oral hypoglycemic Insulin | 3 (6.7) 40 (88.9) | 1 (1.7) 14 (23.7) | ||
Comorbidities | χ2 = 0.11 | 0.94 | ||
No | 20 (44.4) | 28 (47.5) | ||
One comorbidity | 19 (42.2) | 24 (40.7) | ||
Multiple comorbidities | 6 (13.3) | 7 (11.9) | ||
Treatment of COVID | ||||
Supportive | (100) | (100) | χ2 = 8.2 | 0.125 |
Anticoagulant | (64.5) | (50.8) | ||
Steroids | (24.5) | (30.5) | ||
Antiviral | 3 (6.7) | 1(1.7) | ||
Actimra | 2 (4.4) | 1(1.7) | ||
CT picture | χ2 = 1.42 | |||
CO RAD 1 | 4 (8.9) | 10 (16.9) | 0.23 | |
CO RAD 2-5 | 41 (91.1) | 49 (83.1) | ||
ICU admission | ||||
Yes | 25(55.6) | 19 (32.2) | χ2 = 5.7 | 0.01* |
No | 20(44.4) | 40 (67.8) | ||
Intubation | ||||
Yes | 22 (48.9) | 16 (27.1) | χ2 = 5.2 | 0.02* |
No | 23 (51.1) | 43 (72.9) | ||
Discharge | 30 (66.7) | 47 (79.7) | χ2 = 2.24 | 0.134 |
Death | 15 (33.3) | 12 (20.3) |